
|Articles|December 11, 2006
Are transdermal patches the way of the future?
This past April, methylphenidate (Daytrana, Shire) was approved as a transdermal drug delivery system (TD-DDS) for the treatment of attention deficit hyperactivity disorder. And many more patches are on the horizon. Novartis is seeking Food & Drug Administration approval for its rivastigmine (Exelon) patch to aid in the treatment of Alzheimer's disease. Researchers in the United Kingdom are working on a TD-DDS to deliver synthetic cannabinoids for use as antiemetics and appetite stimulants in patients with AIDS and cancer.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
CMS Announces 15 New High-Cost Drugs for Medicare Price Negotiation Program
2
Navigating the Shift: 2026 Medicare Drug Pricing and the Future of Pharmacy
3
AAP Releases Updated Childhood Vaccine Schedule Amid Recent HHS Overhaul
4
Q&A: Pharmacists Combat Vaccine Fatigue by Personalizing Recommendations for Older Adults
5


















